1.93
前日終値:
$1.84
開ける:
$1.84
24時間の取引高:
32,687
Relative Volume:
0.43
時価総額:
$6.17M
収益:
$960.60K
当期純損益:
$-7.10M
株価収益率:
-0.2553
EPS:
-7.56
ネットキャッシュフロー:
$-8.00M
1週間 パフォーマンス:
+2.12%
1か月 パフォーマンス:
+2.12%
6か月 パフォーマンス:
-40.25%
1年 パフォーマンス:
-53.49%
Soligenix Inc Stock (SNGX) Company Profile
SNGX を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
SNGX
Soligenix Inc
|
1.93 | 6.17M | 960.60K | -7.10M | -8.00M | -7.56 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
450.50 | 113.52B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
493.22 | 52.93B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
300.83 | 39.71B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
585.93 | 35.00B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
255.86 | 26.57B | 3.81B | -644.79M | -669.77M | -6.24 |
Soligenix Inc Stock (SNGX) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2020-07-28 | ダウングレード | Dawson James | Buy → Neutral |
2018-01-31 | ダウングレード | H.C. Wainwright | Buy → Neutral |
2017-08-14 | 繰り返されました | Maxim Group | Buy |
2017-07-17 | 開始されました | H.C. Wainwright | Buy |
Soligenix Inc (SNGX) 最新ニュース
Soligenix Highlights Dr. Ellen Kim's Recent Q&A and the Promise - GuruFocus
Soligenix Highlights Dr. Ellen Kim’s Recent Q&A and the Promise of HyBryte™ in Ongoing Clinical Trials - GlobeNewswire
Soligenix Inc. (SNGX) Showcases Promising HyBryte Results in CTCL Treatment Through New Podcast - citybuzz -
Soligenix (NASDAQ: SNGX) Highlights HyBryte Progress in CTCL via New Podcast Featuring Dr. Ellen Kim - Barchart.com
Soligenix (NASDAQ: SNGX) Innovative Treatment to Combat Bacterial Infection Fills Urgent Need for Alternatives to Antibiotics - Barchart.com
Vaccine Contract Manufacturing Market Is Booming Worldwide | - openPR.com
Soligenix’s (NASDAQ: SNGX) HyBryte(TM) Delivers Strong Results In Rare Cancer Trial - Barchart.com
Stocks in play: Brookfield Corporation - The Globe and Mail
Soligenix’s (NASDAQ: SNGX) HyBryte(TM) Delivers Strong Results in Rare Cancer Trial - The Globe and Mail
Chemung Financial Corporation Announces Quarterly Dividend - The Globe and Mail
Soligenix’s HyBryte Shows Promise in Rare Cancer Treatment - citybuzz -
Soligenix (NASDAQ: SNGX) Reports Q1 Milestones, Financial Results - The Globe and Mail
/R E P E A T -- Scotiabank to Announce Second Quarter 2025 Results/ - The Globe and Mail
Public market insider selling at Sprott (SII) - The Globe and Mail
Photodynamic Therapy Market Trends Report 2025-2033, Competitive Analysis of Gladerma, Sun Pharma, Biofrontera, Lumibird, Bausch Health, Soligenix, Modulight, and Theralase TechnologiesResearchAndMarkets.com | FinancialContent - FinancialContent
Zacks Small Cap Predicts Reduced Earnings for Soligenix - Defense World
Zacks Research Issues Business Update as Soligenix (NASDAQ: SNGX) Continues Enrollment in Confirmatory Phase 3 HyBryte Trial - The Globe and Mail
Oral Mucositis Drugs Market Set to Witness Significant Growth - openPR.com
SNGX: Enrollment Continues in Confirmatory Phase 3 Trial of HyBryte™ in CTCL… - MSN
Soligenix Reports Q1 2025 Financial Results and Milestones - TipRanks
SNGX: Enrollment Continues in Confirmatory Phase 3 Trial of HyBryte in CTCL - Research Tree
Contrasting Schrödinger (NASDAQ:SDGR) and Soligenix (NASDAQ:SNGX) - Defense World
Soligenix Announces Recent Accomplishments And First Quarter 2025 Financial Results - Nasdaq
Soligenix Announces Recent Accomplishments And First Quarter 202 - GuruFocus
Soligenix (NASDAQ: SNGX) CEO Highlights Pipeline and Strategy in BioMedWire Podcast Episode - The Globe and Mail
IBN Announces Latest Episode of The BioMedWire Podcast Featuring Dr. Christopher Schaber, CEO of Soligenix Inc. - The Manila Times
Geode Capital Management LLC Has $71,000 Stake in Soligenix, Inc. (NASDAQ:SNGX) - Defense World
Soligenix (NASDAQ: SNGX) HyBryte(TM) Paves Way for Breakthrough Treatment for Rare Skin Cancer - Barchart.com
Soligenix (SNGX) Projected to Post Quarterly Earnings on Friday - Defense World
Soligenix (NASDAQ: SNGX) Moves Forward To Strengthen The Case For HyBryte(TM) - Barchart.com
Soligenix (NASDAQ: SNGX) Moves Forward to Strengthen the Case for HyBryte(TM) - The Globe and Mail
U.S. Severe Oral Mucositis Market Projected To Witness - openPR.com
Press Release Distribution & PR Platform - ACCESS Newswire
Soligenix reports positive results in skin cancer treatment trial By Investing.com - Investing.com India
Fireside Chat with Christopher Schaber, Chief Executive Officer of Soligenix, Inc. - Yahoo Finance
Soligenix reports positive results in skin cancer treatment trial - Investing.com Australia
Solgenix shares rise on positive skin cancer treatment results By Investing.com - Investing.com Canada
Soligenix's HyBryte(TM) Shows 75% Response Rate In Skin Cancer Trial, Backed By FDA Funding - The Globe and Mail
EQS-News: Soligenix's HyBryte(TM) Shows 75% Response Rate In Skin Cancer Trial, Backed By FDA Funding - markets.businessinsider.com
Soligenix (NASDAQ: SNGX) Advances CiVax Amid Ongoing COVID-19 Threat - Barchart.com
Soligenix (NASDAQ: SNGX) Announces Positive Data, Continued Advancement of HyBryte(TM) - The Globe and Mail
Positive Outcome in 75% of CTCL Patients Treated with HyBryte™ f - GuruFocus
SNGX: Updated IIS Data Shows 75% Response Rate and Three Complete Responses… - MSN
Soligenix Announces Positive Data For Extended HyBryte In Early-stage Cutaneous T-cell Lymphoma - Nasdaq
Soligenix Inc (SNGX) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):